Clinical Trials Logo

Hypogonadotropic Hypogonadism clinical trials

View clinical trials related to Hypogonadotropic Hypogonadism.

Filter by:

NCT ID: NCT05971836 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

The Molecular Basis of Inherited Reproductive Disorders

Start date: January 21, 2021
Phase:
Study type: Observational

The goal of this study is to learn more about the genes that control puberty and reproduction in humans.

NCT ID: NCT05896293 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Kisspeptin Administration Subcutaneously to Patients With IHH

Start date: February 3, 2023
Phase: Phase 2
Study type: Interventional

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Gonadotropin-releasing hormone (GnRH) may be administered subcutaneously (SC) for approximately six days in a pulsatile fashion, in order to prime the pituitary gland. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time.

NCT ID: NCT05808647 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Low Energy Availability and Pituitary Function (LEAP Study)

LEAP
Start date: April 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about reproductive hormones and if they change in response to 5-days eating an individualized, standardized diet at two levels: energy balance and low energy intake.

NCT ID: NCT05752591 Completed - Hypogonadism Clinical Trials

Hypothalamic-pituitary Dysfunction in Diabetes

DIAPO
Start date: May 25, 2018
Phase:
Study type: Observational

Type 2 Diabetes mellitus (T2DM) is a chronic disease with a high prevalence and several comorbidities impacting on public health and society. Among the complications of T2DM it has been showed a high prevalence of hypogonadotropic hypogonadism. Even if hypogonadism is associated to a worse metabolic profile and cardiovascular risk, it is discussed whether and when to treat this potentially reversible form associated to diabetes. In fact, the pathogenic mechanism of this condition in diabetic patients is not fully understood, and its clinical correlates, including the prevalence of other possible associated hypothalamic-pituitary axes dysfunctioning, questioned. The aim of the present study is to assess with an observational, cross sectional study on a large series of type 2 diabetic patients, enrolled consecutively: all the suspected etiologies of this complication in one single evaluation (both acquired and genetic congenital predisposition), its clinical correlates and the real prevalence of the disease using the lastly validated criteria for late onset hypogonadotropic hypogonadism.

NCT ID: NCT05633966 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

KASPR
Start date: December 16, 2022
Phase: Phase 1
Study type: Interventional

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

NCT ID: NCT05205837 Terminated - Hypogonadism Clinical Trials

A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Start date: November 24, 2021
Phase: Phase 4
Study type: Interventional

The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function and quality of life.

NCT ID: NCT05184374 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.

NCT ID: NCT04975334 Enrolling by invitation - Clinical trials for Hypogonadotropic Hypogonadism

Opioid Antagonism in Hypogonadotropic Hypogonadism

Start date: August 31, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with idiopathic hypogonadotropic hypogonadism (HH).

NCT ID: NCT04648969 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Start date: January 20, 2021
Phase: Phase 2
Study type: Interventional

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

NCT ID: NCT04456296 Completed - Hypogonadism Clinical Trials

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Start date: June 30, 2020
Phase: Phase 4
Study type: Interventional

Testosterone is the principal androgen produced by the male testes. Hypogonadism is the result of inadequate production of testosterone by the Leydig cells of the testes and is reflected by total serum concentrations of testosterone of < 300 nanograms (ng)/deciliters (dL), with discernible diurnal pattern. The etiology of hypogonadism may be primary or secondary. The treatment of males with primary, and in some cases, secondary hypogonadism includes administration of testosterone. Testim® and Fortesta® are topical gels that when applied daily help to increase the total testosterone levels in the blood through skin absorption. Aveed® is an injectable form of testosterone treatment and participants randomized to this treatment arm will receive 3 injections over the course of 16 weeks. This study is designed to evaluate the effect on blood pressure of approved testosterone products (Testim®, Fortesta®, and Aveed®) after 16 weeks of therapy using 24-hour ambulatory blood pressure to reveal shifts in blood pressure levels.